NCT06822712招募中不适用
A Prospective, Multicenter, Noninferiority, Randomized Controlled Clinical Trial Evaluating the Safety and Efficacy of Sirolimus-coated Coronary Balloon Dilatation Catheter vs Paclitaxel-coated Balloon Catheter for the Treatment of De Novo Coronary Bifurcation Lesions
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Degree of stenosis
研究概览
简要总结
Evaluating the Safety and Efficacy of Sirolimus-coated Coronary Balloon Dilatation Catheter vs Paclitaxel-coated balloon catheter for the Treatment of De Novo Coronary Bifurcation Lesions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants in this clinical trial must meet all of the following criteria:
- •General Inclusion Criteria
- •Age ≥18 years and ≤80 years.
- •Evidence of asymptomatic myocardial ischemia, or stable/unstable angina, or myocardial infarction that occurred more than 7 days before enrollment and is now stable.
- •Suitable for any type of coronary artery revascularization, such as balloon angioplasty, stent implantation, and coronary artery bypass grafting (CABG).
- •Capable of understanding the purpose of the trial, willing to participate, and acknowledging the risks and benefits described in the informed consent document by signing the informed consent form, and willing to undergo invasive imaging follow-up.
- •Angiographic Inclusion Criteria
- •A maximum of 2 vessels requiring treatment, with no more than 3 lesions in total.
- •If the non-target lesion and the target lesion are in the same vessel, the non-target lesion must be located distal to the target lesion.
- •Successful interventional treatment of the non-target lesion prior to the target lesion.
- •Only one true bifurcation lesion requiring treatment (Medina classification 1.1.1, 1.0.1, 0.1.1), with a diameter stenosis ≥70% (by visual estimation) at the ostium of the target lesion side branch.
- •Successful pre-dilation/kissing balloon of the target lesion side branch, no dissection grade C or higher, residual stenosis ≤30% (by visual estimation) in the side branch lesion, and TIMI 3 flow.
- •Suitable for PCI, with the main branch lesion of the target lesion planned for stent implantation without drug-coated balloon treatment, and the side branch lesion treated with a drug-coated balloon without stent implantation; it is recommended to perform kissing balloon dilation for both the main and side branches.
- •Reference diameter of the target lesion side branch 2.0-4.0 mm, and lesion length ≤38 mm.
排除标准
- •If a participant has any of the following conditions, they will be excluded from the study:
- •General Exclusion Criteria
- •Unstable Arrhythmias: Such as high-risk ventricular premature beats or ventricular tachycardia.
- •Severe Heart Failure (New York Heart Association Functional Classification, NYHA Class IV).
- •Preoperative Renal Impairment: Or currently undergoing hemodialysis treatment.
- •Bleeding Tendencies or Contraindications to Antiplatelet Agents and Anticoagulants: Participants who cannot undergo antithrombotic therapy.
- •History of Peptic Ulcer or Gastrointestinal Bleeding within the Past 6 Months: Or history of cerebral hemorrhage, cerebral infarction, or other cerebrovascular accidents (stroke) within the past 6 months.
- •Known Allergies to Contrast Agents, Paclitaxel, Sirolimus, or Their Derivatives.
- •Life Expectancy Less Than 12 Months.
- •Poor Compliance: Participants who, in the investigator's judgment, are unlikely to adhere to the study requirements or are otherwise deemed unsuitable for inclusion.
- •Participation in Other Ongoing Clinical Trials: Participants who have not reached the primary endpoint in other ongoing clinical trials.
- •Pregnant or Lactating Women: Women who plan to conceive within 12 months or are unwilling to use effective contraception.
- •Angiographic Exclusion Criteria
- •Left Main Trunk and Its Bifurcation Lesions Requiring Treatment.
- •Thrombus in the Target Lesion: Excessive tortuosity of the vessel, making it unlikely for the balloon to pass through the lesion.
- •Total Occlusion in the Side Branch Lesion of the Target Lesion.
- •Severe Calcification in the Side Branch Lesion of the Target Lesion: Lesions that cannot be pre-dilated or treated with double-balloon kissing dilation.
- •In-Stent Restenosis in the Target Vessel (Including Both Main and Side Branches).
- •Residual Stenosis >30% (by Visual Estimation) or Dissection Grade C or Higher After Pre-Dilation or Double-Balloon Kissing Dilation of the Side Branch Lesion of the Target Lesion.
结局指标
主要结局
Degree of stenosis
时间窗: 9 Months postoperatively
Degree of stenosis (%) of target bifurcation lesion segment diameter at 9 months postoperatively (Measured by QCA)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for Coronary Small VesselsCoronary Artery DiseaseNCT06345209BrosMed Medical Co., Ltd236
已完成
4 期
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)Coronary Artery DiseaseNCT01078038Seung-Jung Park451
招募中
不适用
Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery StenosisPeripheral Artery DiseaseNCT04982367Acotec Scientific Co., Ltd166
已完成
4 期
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)Coronary Artery DiseaseNCT01186094Seung-Jung Park502
进行中（未招募）
不适用
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM IICoronary Artery StenosisCoronary Artery DiseaseNCT04893291Fondazione Ricerca e Innovazione Cardiovascolare ETS1,820